Biostar Pharmaceuticals, Inc. (BSPM)

[finesand]

Relevant for 4Q17 and 2018 Revenue?

2016-10-11 Launch a New Product Aimed at Treating Effects of Rhinitis and Sinusitis

$7.5M within 2 years starting in 2017?
So far, none has been recognized in 2017 of this product.
Potential to give a positive surprise in either quarter 4Q17 - 2Q18 inclusive.

The Chairman continued: "In the past several months, we have been preparing various steps necessary for the launch of this new product. Though we do not anticipate any significant sales revenue in 2016, we expect to sell approximately 400,000 units within the next 2 years, which is expected to yield approximately RMB50 million (or US$7.5 million)."